Age-related Macular Degeneration // Clinical Trials // Geographic Atrophy // Kathleen Schildroth // Past // Dec 01 2020
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA)
Sponsor: NGM Biopharmaceuticals, Inc.